Spatially Fractionated Radiotherapy for Bulky Tumors
Official title: Spatially Fractionated Radiotherapy for Bulky or Refractory Solid Tumors: Efficacy and Toxicity
Run by The University of Hong Kong-Shenzhen Hospital · NCT07774819 · Data updated 2026-11-12
This study tests a new way of giving radiation in big tumors to see if it can shrink tumors with less long-term damage to normal tissue.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 126 (estimated) |
| Sponsor | The University of Hong Kong-Shenzhen Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Shenzhen, Guangdong) |
| Status | Recruiting |
| Started | December 19, 2024 |
| Main results expected | December 2028 |
| Study ends | December 2028 |
| Registry record updated | August 19, 2026 |
| Trial ID | NCT07774819 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with bulky solid tumors (>4 cm) or refractory solid tumors, without hollow-organ involvement at high bleeding risk and who can reliably care for themselves.
✕Probably not a fit
Patients with hollow-viscera–involved tumors at high risk of bleeding or perforation, or patients unable to care for themselves may have limited benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional trial assesses the safety and preliminary effectiveness of spatially fractionated radiotherapy (SFRT), also known as lattice radiotherapy, for bulky solid tumors. SFRT delivers alternating high-dose and low-dose subregions within the tumor to maximize tumor control while minimizing irradiation of surrounding healthy tissue. The trial includes patients with bulky solid tumors (diameter >4 cm) or refractory solid tumors who meet specific eligibility criteria, and excludes tumors involving hollow organs at high risk of bleeding and patients who cannot care for themselves. Outcomes focus on toxicity and local tumor response, with results expected to inform feasibility of SFRT as a precision radiotherapy option for large or resistant tumors.
Why it matters
Potential benefit: If successful, SFRT could improve tumor control while reducing radiation-associated toxicity in bulky cancers.
How similar studies have gone: Previous lattice/space-fractionated radiotherapy approaches have shown encouraging responses in bulky tumors, but this exact protocol represents an emerging, exploratory strategy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a bulky solid tumor with a maximum diameter \>4 cm or a refractory solid tumor. Exclusion Criteria: * Tumors involving hollow viscera that are considered to have a clinically significant risk of bleeding or perforation. * Patients with impaired consciousness or who are unable to care for themselves.
Where it's running
-
The University of Hong Kong - Shenzhen Hospital
Shenzhen, Guangdong, China Recruiting
Study contacts
- Study coordinator: Zhiyuan Xu, MD
- Email: xuzy@hku-szh.org
- Phone: +86 0755-86913333
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
-
Low-dose radiation to boost elranatamab for relapsed/refractory multiple myeloma with extramedullary or paramedullary disease
We will test whether low-dose radiation given before elranatamab helps people with relapsed or refractory multiple myeloma that has grown outside the bone or into surrounding tissue respond better to treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.